Pacer Advisors’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.48M | Sell |
5,883
-54
| -0.9% | -$13.4K | ﹤0.01% | 1069 |
|
|
2025
Q4 | $1.63M | Sell |
5,937
-248
| -4% | -$67.8K | ﹤0.01% | 1208 |
|
|
2025
Q3 | $1.62M | Sell |
6,185
-350
| -5% | -$85.1K | ﹤0.01% | 1182 |
|
|
2025
Q2 | $1.43M | Buy |
6,535
+2,852
| +77% | +$610K | ﹤0.01% | 1138 |
|
|
2025
Q1 | $825K | Sell |
3,683
-2,097
| -36% | -$578K | ﹤0.01% | 1275 |
|
|
2024
Q4 | $1.89M | Sell |
5,780
-2,862
| -33% | -$901K | ﹤0.01% | 1029 |
|
|
2024
Q3 | $2.59M | Buy |
8,642
+68
| +0.8% | +$20.8K | 0.01% | 853 |
|
|
2024
Q2 | $2.82M | Buy |
8,574
+1,303
| +18% | +$460K | 0.01% | 804 |
|
|
2024
Q1 | $2.88M | Sell |
7,271
-78
| -1% | -$28.9K | 0.01% | 734 |
|
|
2023
Q4 | $2.59M | Sell |
7,349
-427
| -5% | -$151K | 0.01% | 720 |
|
|
2023
Q3 | $2.92M | Sell |
7,776
-1,033
| -12% | -$399K | 0.01% | 541 |
|
|
2023
Q2 | $3.37M | Buy |
8,809
+1,786
| +25% | +$638K | 0.01% | 600 |
|
|
2023
Q1 | $2.43M | Buy |
7,023
+6,282
| +848% | +$1.84M | 0.01% | 676 |
|
|
2022
Q4 | $174K | Sell |
741
-1,625
| -69% | -$385K | ﹤0.01% | 2300 |
|
|
2022
Q3 | $582K | Buy |
2,366
+58
| +3% | +$17.7K | ﹤0.01% | 699 |
|
|
2022
Q2 | $698K | Sell |
2,308
-1,569
| -40% | -$511K | 0.01% | 616 |
|
|
2022
Q1 | $1.59M | Sell |
3,877
-1,006
| -21% | -$394K | 0.01% | 690 |
|
|
2021
Q4 | $2.29M | Sell |
4,883
-645
| -12% | -$278K | 0.02% | 741 |
|
|
2021
Q3 | $2.35M | Sell |
5,528
-245
| -4% | -$103K | 0.03% | 640 |
|
|
2021
Q2 | $2.07M | Buy |
5,773
+1,499
| +35% | +$495K | 0.03% | 614 |
|
|
2021
Q1 | $1.2M | Sell |
4,274
-433
| -9% | -$124K | 0.02% | 692 |
|
|
2020
Q4 | $1.33M | Sell |
4,707
-2,417
| -34% | -$678K | 0.03% | 579 |
|
|
2020
Q3 | $1.96M | Sell |
7,124
-1,663
| -19% | -$440K | 0.04% | 424 |
|
|
2020
Q2 | $2M | Buy |
8,787
+8,710
| +11,312% | +$1.71M | 0.04% | 364 |
|
|
2020
Q1 | $13K | Sell |
77
-25,060
| -100% | -$3.86M | ﹤0.01% | 598 |
|
|
2019
Q4 | $3.78M | Sell |
25,137
-2,366
| -9% | -$344K | 0.17% | 104 |
|
|
2019
Q3 | $3.9M | Sell |
27,503
-2,117
| -7% | -$291K | 0.09% | 239 |
|
|
2019
Q2 | $3.71M | Buy |
29,620
+29,502
| +25,002% | +$3.48M | 0.09% | 231 |
|
|
2019
Q1 | $13K | Sell |
118
-89
| -43% | -$9.26K | ﹤0.01% | 712 |
|
|
2018
Q4 | $20K | Sell |
207
-25,269
| -99% | -$2.74M | ﹤0.01% | 394 |
|
|
2018
Q3 | $3.15M | Buy |
25,476
+2,201
| +9% | +$247K | 0.12% | 161 |
|
|
2018
Q2 | $2.31M | Buy |
23,275
+3,187
| +16% | +$293K | 0.1% | 222 |
|
|
2018
Q1 | $1.77M | Buy |
20,088
+2,211
| +12% | +$207K | 0.1% | 238 |
|
|
2017
Q4 | $1.76M | Buy |
17,877
+7,270
| +69% | +$713K | 0.12% | 191 |
|
|
2017
Q3 | $1.02M | Buy |
10,607
+1,348
| +15% | +$122K | 0.09% | 282 |
|
|
2017
Q2 | $875K | Sell |
9,259
-396
| -4% | -$36.4K | 0.09% | 300 |
|
|
2017
Q1 | $788K | Buy |
9,655
+1,549
| +19% | +$130K | 0.1% | 273 |
|
|
2016
Q4 | $687K | Buy |
8,106
+385
| +5% | +$30.3K | 0.1% | 258 |
|
|
2016
Q3 | $575K | Buy |
7,721
+742
| +11% | +$58.9K | 0.09% | 302 |
|
|
2016
Q2 | $529K | Buy |
6,979
+5,837
| +511% | +$425K | 0.08% | 302 |
|
|
2016
Q1 | $79K | Buy |
+1,142
| New | +$68.7K | 0.02% | 691 |
|
Other funds holding WST
VCM
VPM
GIM
Pacer Advisors's WST Position: Q1 2026 in Review
Pacer Advisors reduced its West Pharmaceutical (WST) stake by 0.91% in Q1 2026, selling an estimated $13.4K and leaving 5,883 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1069.
Pacer Advisors first reported a position in WST in Q1 2016 and has held it in 41 quarters since. The position peaked at $3.9M in Q3 2019. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.
- Pacer Advisors held 5,883 shares of West Pharmaceutical worth $1.48M as of Q1 2026.
- Pacer Advisors sold 54 West Pharmaceutical shares in Q1 2026, an estimated $13.4K.
- West Pharmaceutical made up ﹤0.01% of Pacer Advisors's portfolio in Q1 2026, its #1069 holding.
- Pacer Advisors first reported a position in West Pharmaceutical in Q1 2016 and has held it in 41 quarters since.
- Pacer Advisors's West Pharmaceutical position peaked at $3.9M in Q3 2019.
- 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.